• Relmada Therapeutics reported interim Phase 2 NDV-01 complete response rates of 94% overall and 77% at 12 months in high-risk bladder cancer.
• No grade 3 or higher treatment-related adverse events occurred; no patients discontinued because of treatment-related adverse events.
• At 18 months, 12 of 14 evaluable long-term extension patients remained in complete response; two patients developed muscle-invasive disease at month 15.
• The planned SPECTRUM program includes two independent registrational cohorts: 87 high-risk patients and 276 intermediate-risk patients, with the latter enrollment under review.
• An investigational new drug application for NDV-01 is planned by year-end 2026, with registrational trials starting upon clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.